Media stories about ProNAi Therapeutics (NASDAQ:SRRA) have been trending positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 47.0855537238537 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of ProNAi Therapeutics (SRRA) opened at $2.58 on Friday. ProNAi Therapeutics has a 12-month low of $1.10 and a 12-month high of $2.64.

ProNAi Therapeutics (NASDAQ:SRRA) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. research analysts forecast that ProNAi Therapeutics will post -0.85 EPS for the current fiscal year.

A number of equities research analysts have issued reports on SRRA shares. Zacks Investment Research lowered ProNAi Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Jefferies Group LLC raised ProNAi Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, October 23rd. Finally, ValuEngine raised ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. ProNAi Therapeutics has a consensus rating of “Hold” and an average target price of $4.00.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/11/25/pronai-therapeutics-srra-getting-positive-press-coverage-accern-reports.html.

About ProNAi Therapeutics

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Insider Buying and Selling by Quarter for ProNAi Therapeutics (NASDAQ:SRRA)

Receive News & Stock Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related stocks with our FREE daily email newsletter.